Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
...this was a headline and a half :
*Merck Voluntarily Withdrawing U.S. Indication for KEYTRUDA for Treatment of Metastatic Small Cell Lung Cancer With Disease Prog
(Dow Jones) -- (MORE TO FOLLOW) Dow Jones Newswires
no problem - but that’s what half the money is for
..its fact, currently we have 16000 investors ( apparently ) and we are literally unheard of ...
there will be tens of millions of people alerted on day one ( just remember the BBC JTM article on UK TV ? there’s 10M straight away ) of which a few hundreds thousands will want to buy of which 20k will actually find a way ....
...additionally they will have no clue that the outstanding shares of 850m is in fact 1.3bn and will buy
blinded .
I think you're probably right BUT it also probably suggests to those that have been sitting on the sideline deciding whether to de risk their shares vs keeping their warrants that its safe to do so ... I think we will pick up from these high 20's by the close ...but what do I know ..
agreed all warrant related selling ( not warrant conversion )
8K
Item 1.01. Entry into a Material Definitive Agreement.
Loan Entered Into
On March 1, 2021, Northwest Biotherapeutics, Inc. (the “Company”) entered into a Commercial Loan Agreement and Note (collectively, the “Loan Agreement”) with Streeterville Capital, LLC (the “Holder”) in the amount of $11,005,000. The Loan Agreement has a maturity of 22 months. Repayments do not start until November 1, 2021.
Following November 1, 2021, the Loan Agreement will be amortized in 14 equal monthly installments of principal at 110% of the pro rata amount, plus accrued interest. Interest on the Loan Agreement accrues at a rate of 8% per annum, and the Loan Agreement includes an original issue discount of ten percent. The Loan Agreement allows pre-payment at any time at the Company’s election. If the Company elects to pre-pay, the pre-payment would include a 10% charge. The Loan Agreement contains customary default provisions, including for potential acceleration.
*AMGEN TO BUY FIVE PRIME THERAPEUTICS FOR $1.9B IN CASH
...thats about 79% premium on COB last night and btw their stock price was in a downtrend
Five Prime Therapeutics, Inc. provides clinical stage biotechnology services. The Company offers innovative proteins, antibody therapeutics, and drugs for oncology and immunology diseases. Five Prime Therapeutics serves customers in the United States.
Back in November :
Five Prime Therapeutics Says Trial Shows Positive Results From Trial of Bemarituzumab Plus Chemotherapy Compared With Placebo
(MT Newswires)
Five Prime Therapeutics (FPRX) said Tuesday that its Phase 2 Fight trial, which compared mFOLFOX6 chemotherapy plus bemarituzumab with placebo plus chemotherapy in patients with front-line advanced gastric and gastroesophageal junction cancer, showed positive results.
The three efficacy points of the trial, progression-free survival, overall survival, and objective response rate, met pre-specified statistical significance.
you are 100% wrong on CGT
'Based on the understood method by which UV-C exposure deactivates pathogens, we would expect UV-C disinfection lighting to have a similar impact on the various genetic mutations of (SARS-CoV2)."
Sam Kabbani
Chief Scientific Officer at Innovative Bioanalysis
I believe TLD before end March
Ha that`s right , California kid used to finish everything `yee haw !! `
Other ppsters used to just post ` boom` all day and of course it never was boom...
I`d never seen a message board before that, I couldn't believe this murky underworld actually went on ..
Ides is 15th ..
...yes but when KIPK...but when ...
..People in the UK that de risked due to imminent huge CGT tax raises ( 20% to 45% ) expected in today budget will be buying back in today as the current rate of 20% has just been fixed for the next 5 years.....phew ...
Easy ...
1. It [DCVax-l] ( with ketel one ) is good for the patients. Adam Feurstein
2. There are many different types of vaccines... Here at UCLA, we use the dendritic cell vaccine. Maxim Jabobs
3. A lot of these patients, if we treat them [with DCVax-l] early on, are living long term. Learnign Curve
4. We also have to work with the regulatory bodies, and we probably ought to do that now, right, not even waiting, because we want this to be available to all the patients. Again, while it’s very nice about these studies… yes, those patients who are in better prognostic groups are going to benefit more… but there is a benefit to all patients. We want this available to absolutely everybody. Prof Ashkan on behalf of Turtle
5. Immunotherapies available at UCLA include:
Vaccines: Vaccines are among the most promising immunotherapies. Researchers at UCLA developed the first personalized vaccine for brain tumors (dendritic cell-based vaccine, or DCVax®). DCVax® has extended survival of many of our glioblastoma patients for more than a year, and some are thriving more than 10 years after their initial diagnosis. California Kid ( yahoo message board 2013-2014 )
Correct
Thats because it isnt ..
That`s a great find ..well done..
I mean honestly we should, be through $2 off the back of that alone ...
Utter rubbish Ae please think about this stuff before you post it..
utter rubbish Ae please thing about this stuff be fore you post it
Merck US Market Cap has dropped $30bn ( $215bn to $185bn cob last night ) in the last month and is back to last Aprils lows .. they have to act ...
Ha ... agreed agreed and agreed ...
thats is very helpful indeed , thanks AP
thank you very much flipper
Urgent help
I know a young person , 24 that has been diagnosed with
inoperable brain tumour called a Grade 3 Anaplastic Astrocytoma.
Before I get their hopes up is this something that
DCVAX L has had any impact on ??
Many thanks.
Oilpatch
...do we know what the actual trial completion date was ?
They PR'rd data lock on 5th October but that doesn't mean that data lock hadn't actually occurred weeks or months before.
I`m convinced they waited at least a month if not a lot more between actual DL and PR'ing it..
Also what is the definition of the `trial completion data`, is it definitely actual data lock ?
Anyway as i said I`m convinced that right now we are at least 5 and very possibly 6 months since actual data lock.
Thanks
i was watching him mess around with the order in the stack , amateur whoever he is ..
who ever the
d1ck was that was offering 200k at 1.44 has chased it down and it looks like he`s nearly all out .
,,,all bio M&A makes me think of IMMU and its Breast Cancer
drug being bought by GILD for $21bn , for us that's a $15 pps
Only floated on 17th July 2020..
Merck to Buy Pandion Therapeutics for $1.85B Cash: M&A Snapshot
PANDION THERAPEUTICS INC FIGIBBG00VR8VX16
Classification Biotech
Pandion Therapeutics, Inc. operates as a biotechnology company. The Company focuses on
developing therapeutics, such as modular proteins, antibodies and bispecifics for the treatment of people with autoimmune and inflammatory diseases.
Pandion Therapeutics serves customers in the State of Massachusetts.
Merck to Acquire
Pandion Therapeutics
Acquisition Adds Pipeline of Candidates Targeting a Broad Range of Autoimmune Diseases
Business Wire
KENILWORTH, N.J & WATERTOWN, Mass. -- February 25, 2021
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Pandion Therapeutics, Inc. (Nasdaq: PAND) today announced that the companies have entered into a definitive agreement, under which Merck, through a subsidiary, will acquire Pandion, a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, for $60 per share in cash. This represents an approximate total equity value of $1.85 billion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210225005318/en/
Good luck Jimmy ,
I`m involved in the SPAC world as well, seismic shifts towards tokenisation will change the IPO market forever.
Tokenisation will in part ensure no shorting.
Flipper ,
I remember him waxing lyrical about the valuation of the Sawston estate
you`d have thought he was a local surveyor he spoke with such authority but luckily it was at that point I realised that he was full of it...so he joined the red dot brigade . He's a retired very bitter and twisted old man and one to be avoided .
Try reading Trading in the Zone, admittedly its day trading and nothing to do with single stocks , but its very very good and will compliment your TA edge
no matter where we close today Soj , that was a top end call, you should be trading 10 year Bund futures ..